01695nas a2200205   4500008004100000022001400041245010500055210006900160260000800229300001100237490000800248520097100256653002401227653001501251653002301266100002301289700002401312700002501336856012801361       2024                        eng d  a0040-403900aAlternative synthetic route for the pharmacophore of anticancer agent: triazolopyridazine derivative0 aAlternative synthetic route for the pharmacophore of anticancer   cAUG  a1551930 v1463 a<p>
	ATAD2 has received attention as one of the potential oncogene with tumor-promoting aspects in many malignancies. ATAD2 is a highly conserved bromodomain family protein that exerts its biological functions by mainly AAA ATPase and bromodomain. Several small molecule inhibitors have been described in the literature. AZ13824374 (1) recently reported by Holt and co-workers showed promising in vitro (bio-chemical, cellular) and antiproliferative activity in range of breast cancer models. In this work, we described scalable synthetic route for triazolopyridazine derivative (2), a key intermediate of AZ13824374 (1) without using CO in the process. Triazolopyridazine helps to attain the bioactive conformation for AZ13824374 (1) through its crucial interaction with Tyr 1021 of ATAD2. Additionally, triazolopyridazine is extensively used as an intermediate for anticancer agents. This encouraged us to develop cost-effective and scalable process for it.</p>
10aAlternative process10aAnticancer10aTriazolopyridazine1 aKarche, Ranjit, S.1 aBankar, Shubham, R.1 aJadhav, Vrushali, H.  uhttps://library.ncl.res.in/content/alternative-synthetic-route-pharmacophore-anticancer-agent-triazolopyridazine-derivative